Vanda Pharmaceuticals (STU:VM4) Cyclically Adjusted PB Ratio: (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:VM4 Vanda Pharmaceuticals Inc STU:VM4
74 GF Score
Price €4.32
GF Value €4.42
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vanda Pharmaceuticals  (STU:VM4) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.58 1.34 0.65 0.64 1.10

Vanda Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.63 1.10 0.85 0.00

STU:VM4 vs LYEL, ZNTL, PROK: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


STU:VM4
74GF Score
Vanda Pharmaceuticals Inc STU:VM4
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vanda Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Vanda Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.173/333.9520*333.9520
=3.173

Current CPI (Jun. 2026) = 333.9520.

Vanda Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 2.620 241.428 3.624
201612 2.830 241.432 3.914
201703 2.690 243.801 3.685
201706 2.608 244.955 3.556
201709 2.437 246.819 3.297
201712 2.471 246.524 3.347
201803 3.753 249.554 5.022
201806 4.107 251.989 5.443
201809 4.275 252.439 5.655
201812 4.613 251.233 6.132
201903 4.652 254.202 6.111
201906 4.930 256.143 6.428
201909 6.825 256.759 8.877
201912 6.907 256.974 8.976
202003 6.961 258.115 9.006
202006 7.016 257.797 9.089
202009 6.839 260.280 8.775
202012 6.791 260.474 8.707
202103 7.070 264.877 8.914
202106 7.180 271.696 8.825
202109 7.527 274.310 9.164
202112 7.994 278.802 9.575
202203 8.071 287.504 9.375
202206 8.507 296.311 9.588
202209 9.203 296.808 10.355
202212 8.764 296.797 9.861
202303 8.711 301.836 9.638
202306 8.667 305.109 9.486
202309 8.846 307.789 9.598
202312 8.685 306.746 9.455
202403 8.600 312.332 9.195
202406 8.647 314.175 9.191
202409 8.363 315.301 8.858
202412 8.820 315.605 9.333
202503 8.027 319.799 8.382
202506 7.137 322.561 7.389
202509 6.718 324.800 6.907
202512 4.728 324.054 4.872
202603 4.039 330.213 4.085
202606 3.173 333.952 3.173

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Vanda Pharmaceuticals (STU:VM4) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be undervalued. The current stock price of €4.32 is trading 2.2% below its estimated GF Value™ of €4.42. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for STU:VM4:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €4.42 vs. price of €4.32 (2.2% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the STU:VM4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USA0LKB:UK
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
74GF Score

Get the complete analysis for STU:VM4

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.32
Price
€4.42
GF Value